Results 21 to 30 of about 5,401 (177)

A Non-interventional Study on Vismodegib for Basal Cell Carcinoma With A Treat-To-Target Regimen In Swedish Patients

Dermatology Practical & Conceptual, 2023
Introduction: Real-life data on vismodegib in advanced basal cell carcinoma (aBCC) are limited. Optimal treatment duration is left to the discretion of the physician. Objectives: To assess the effectiveness, safety and treatment pattern for vismodegib
Niels Bendsöe, John Paoli, Karin Söderkvist, Bertil Persson, Christina Halldin, Linda Ihrlund, Maria Wolodarski   +6 more
doaj   +1 more source

The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo

Pharmaceutics, 2021
Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects.
Maria Natalia Calienni, Daniela Maza Vega, C. Facundo Temprana, María Cecilia Izquierdo, David E. Ybarra, Ezequiel Bernabeu, Marcela Moretton, Fernando C. Alvira, Diego Chiappetta, Silvia del Valle Alonso, María Jimena Prieto, Jorge Montanari   +11 more
doaj   +1 more source

Vismodegib [PDF]

Clinical Cancer Research, 2012
Abstract Vismodegib (GDC-0449), an orally bioavailable small-molecule inhibitor of Hedgehog signaling, was recently approved by the U.S. Food and Drug Administration for the treatment of basal cell carcinoma that is either metastatic or locally advanced in patients who are not candidates for surgical resection or radiation.
openaire   +3 more sources

Low-Dose Vismodegib as Maintenance Therapy After Locally Advanced Basal Cell Carcinoma Complete Remission: High Efficacy with Minimal Toxicity

Dermatology and Therapy, 2020
Introduction Locally advanced basal cell carcinoma (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI) vismodegib has provided an effective, well-tolerated therapy.
Massimiliano Scalvenzi, Milena Cappello, Claudia Costa, Gabriella Fabbrocini, Mariaantonietta Luciano, Alessia Villani   +5 more
doaj   +1 more source

Tolerance of sonidegib after intolerance of vismodegib—Experience in two patients with nevoid basal cell carcinoma syndrome (Gorlin syndrome)

Skin Health and Disease, 2023
Nevoid basal cell carcinoma syndrome (NBCCS, Gorlin syndrome) is a rare genetic condition characterized by the early development of numerous cutaneous basal cell carcinomas (BCCs).
Federico Venturi, Luciana Trane, Flavia Silvestri, Biancamaria Zuccaro, Elisabetta Magnaterra, Vincenzo De Giorgi   +5 more
doaj   +1 more source

Vismodegib for treatment of periocular basal cell carcinoma – 6-year experience from a tertiary cancer center, [PDF]

Anais Brasileiros de Dermatologia, 2022
Background: The treatment of advanced periocular basal cell carcinomas becomes a challenge as surgery may involve highly mutilating procedures. Vismodegib is the first selective hedgehog inhibitor approved for the treatment of locally advanced tumors or ...
Catarina Xavier, Edgar Lopes, Catarina Bexiga, Cecília Moura, Emanuel Gouveia, Ana Filipa Duarte   +5 more
doaj   +1 more source

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS

Acta Dermato-Venereologica, 2022
Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally ...
Martin Kaatz, Peter Mohr, Elisabeth Livingstone, Michael Weichenthal, Alexander Kreuter, Claudia Pföhler, Ulrike Leiter, Jens Ulrich, Jochen Sven Utikal, Ralf Gutzmer, Rudolf Herbst, Dirk Schadendorf   +11 more
doaj   +1 more source

Advanced basal cell carcinoma treated with vismodegib

, 2020
A. 64 yowf with nodular and micronodular BCC on back. Treated with vismodegib 150mg Mon-Fri with tumor shrinkage to 23 by 7cm after a six month course and treated subsequently with a radical resection and removal of T2-L1 spinous processes.
Wong, C (via Mendeley Data)
core   +2 more sources

Vismodegib: A Review

Actas Dermo-Sifiliográficas (English Edition), 2014
In January 2012, vismodegib (Erivedge, manufactured by Genentech) became the first selective inhibitor of the Hedgehog signaling pathway to be approved by the US Food and Drug Administration for the treatment of locally advanced and metastatic basal cell carcinoma.
V, Ruiz-Salas, M, Alegre, A, López-Ferrer, J R, Garcés   +3 more
openaire   +2 more sources

Raman Spectroscopy to Monitor the Delivery of a Nano-Formulation of Vismodegib in the Skin

Applied Sciences, 2023
Raman spectroscopy was used to detect low quantities of Vismodegib in the skin after its topical application via transfersomes. Vismodegib is a novel antineoplastic drug approved for oral administration for treatment of basal cell carcinoma ...
Gisela Eliane Gómez, María Natalia Calienni, Silvia del Valle Alonso, Fernando Carlos Alvira, Jorge Montanari   +4 more
doaj   +1 more source